Navneet Singh: Expert consensus statement on the peri-operative management of NSCLC
Navneet Singh, Thoracic Medical Oncologist at the Postgraduate Institute of Medical Education and Research, shared a post on LinkedIn about a recent paper by him and colleagues published in Lung Cancer Journal:
“Now published our Asian Thoracic Oncology Group consensus on perioperative management of NSCLC.
Rapid and recent advances in treatment with targeted therapies and immunotherapy for cases with and without oncogenic driver alterations (EGFR, ALK) have revolutionised the management of early-stage lung cancer.
Provided algorithms are based on currently available evidence. Also discussed are potential areas for research that may further help refine treatment algorithms in the future.”
Authors: Stephanie Saw, Wen-Zhao Zhong, Rui Fu, Thanyanan Reungwetwattana, Navneet Singh et al.
More posts featuring Navneet Singh.
Dr. Navneet Singh, a Thoracic Medical Oncologist and a Professor at the Postgraduate Institute of Medical Education and Research (PGIMER), specializes in non-small cell lung cancer (NSCLC) treatment, focusing on targeted therapies and immunotherapy.
He leads PGIMER’s thoracic oncology group, which won the Lung Cancer Care Team Award at the 2019 WCLC. Dr. Singh received the Clifton Mountain Lectureship Award in 2023.
Dr. Navneet is a member of Member of Staging and Prognostic Factors Committee at the International Association for the Study of Lung Cancer and a Member of Cancer Medicines Committee at ESMO – European Society for Medical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023